Y-mAbs Therapeutics announced that the FDA has cleared the company’s investigational new drug, or IND, application for CD38-SADA, the company’s second program within its Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy Theranostic Platform. The Phase 1 trial is a first-in-human, dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex in patients with Relapsed or Refractory non-Hodgkin Lymphoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
- Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
- Y-mAbs Announces Publication in Cancers
- Y-mAbs announces publication of naxitamab-based chemoimmunotherapy data
- Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology